Retatrutide, a novel dual activator of the GLP-1 receptor and glucose-dependent insulinotropic polypeptide (GIP) target, is showing promising results in preliminary patient assessments . Current research https://shopretatrutidepeptide.com/retatrutide-research-knowledge-hub/